A Relationship of Periostin with some Bio- parameters in Type2 Diabetic Patients without and with COVID19
Journal of University of Anbar for Pure Science,
2022, Volume 16, Issue 1, Pages 27-32
AbstractBackground: Type 2diabetes mellitus (T2DM) is a prolonged disease characterized by hyperglycemia resultant from weakening in insulin secretion, insulin action or both. T2DM and its associated metabolic disorders have been stated as the main cause in coronavirus disease 2019 (COVID-19). Current study was designed to investigate the association of periostin with some parameters in T2DM patients without and with COVID19.
Materials and methods: This study involved of 56 patients, 28 with T2DM without any complications, the other 28 have T2DM with COVID19 attending Al-Fallujah teaching hospital, and 28 healthy persons matching in age, gender and ethnic background as control group. Serum level of periostin was estimated by ELISA technique while urea and creatinine were assessed by colorimetric enzymatic methods. Total protein and albumin were determined by biuret method.
Results: Serum level of periostin was elevated in the T2DM patients without and with COVID19 than in healthy controls (HCs). The levels of urea and creatinine were importantly higher in T2DM patients without and with COVID 19 than in HCs (P < 0.000l), while total protein and albumin were lower in T2DM patients without and with COVID 19 than in HCs (P < 0.000l). Periostin had significant positive association with fasting serum glucose (FSG), HbA1c, urea creatinine, BMI, and ALB/GLB (P Conclusion: Serum level of periostin may be used as a novel biomarker in diagnosis T2DM without and with COVID19.
1. Diabetes Canada Clinical Practice Guidelines Expert Committee. (2018). Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes; 42(Suppl 1): S1-325.
2. Berlin DA, Gulick RM, Martinez FJ. (2020). Severe Covid-19. N Engl J Med 383: 2451-60
3. Conway SJ, Izuhara K, Kudo Y and et al. (2014). The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci; 71(7):1279–1288.
4. Snider P, Standley KN, Wang J, et al. (2009). Origin of cardiac fibroblasts and the role of periostin. Circ Res; 105(10):934–947.
5. Azharuddin M, Adil M, Ghosh Pand et al. (2019). Periostin as a novel biomarker of cardiovascular disease: a systematic evidence landscape of preclinical and clinical studies. J Evid Base Med; 12(4):325–336.
6. Luo Y, Qu H, Wang H and et al. (2016). Plasma periostin levels are increased in Chinese subjects with obesity and type 2 diabetes and are positively correlated with glucose and lipid parameters. Mediat Inflamm; 2016(6423637):1-6.
7. Dong D, Jia L, Zhang L et al. (2018). Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci; 109(9):2841-2851.
8. Liu Y, Li F, Gao F and et al. (2017). Role of microenvironmental periostin in pancreatic cancer progression. Oncotarget; 8(52):89552-89565.
9. Satirapoj B, Tassanasorn S, Charoenpitakchai M and et al. (2015). Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus. PLoS One 10:e0124055.
10. Yoshida S, Ishikawa K, Asato R and et al. (2011). Increased expression of periostin in vitreous and membranes obtained from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci; 52:5670–5678.
11. Ohta S, Okamoto M, Fujimoto K and et al. (2017). The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One. 2017; 12(3):e0174547.
12. Liu AY, Zheng H, Ouyang G. Periostin. (2014). A multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol; 37: 150-156.
13. Takayama G, Arima K, Kanaji T and et al. (2006). Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol; 118: 98-104.
14. Conway SJ, Izuhara K, Kudo Y and et al. (2014). The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci; 71: 1279-1288.
15. Kazakou P, Paschou SA, Psaltopoulou T, et al.(2021). Early and Late Endocrine Complications of COVID-19. Endocr Connect; 10(9):R229–39..
16. Lim S, Bae JH, Kwon H-S, et al. (2021). COVID-19 and Diabetes Mellitus: From Pathophysiology to Clinical Management. Nat Rev Endocrinol; 17(1):11–30.
17. Apicella M, Campopiano MC, Mantuano M and et al. (2020). COVID-19 in People With Diabetes: Understanding the Reasons for Worse Outcomes. Lancet Diabetes Endocrinol; 8(9):782–92.
18. Drucker DJ. (2020). Coronavirus Infections and Type 2 Diabetes—Shared Pathways With Therapeutic Implications. Endocr Rev; 41(3):457–70.
19. Cabalak M, Doğan S, Bal T et al. (2021). Serum periostin levels in COVID-19: Is it useful as a new biomarker?. Int J Clin Pract; 00:e14728: 1-6.
20. Fayez, S.S., Rashied, R.M., Al-Alaaraji, S.F.T. (2020). Evaluation of serum clusterin levels in type 2 diabetic men with and without cardiovascular disease. Iraqi Journal of Science, 61(5): 978–984.
21. Abbas, K.M., Alaaraji, S.F.T., Al – Shawk, R.S. (2020). Astudy of the association between IL-17 and HOMA-IR in Iraqi type 2 diabetic patients. Iraqi Journal of Science, 61(3): 491–498.
22. Zhang N, Wang C, Zhu Fand et al. (2020). Risk Factors for Poor Outcomes of Diabetes Patients with COVID-19: a Single-Center, Retrospective Study in Early Outbreak in China. Front Endocrinol; 24 (11):571037.
23. Gupta S, Hayek SS, Wang W and et al. (2020). Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med; 180(11):1436–1447.
24. Petrilli CM, Jones SA, Yang J and et al. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ; 369:m1966..
25. Tang N, Li D, Wang X, Sun Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost; 18(4):844–847.
26. Logette E , Lorin C, Favreau C and et al. (2021). Elevated Blood Glucose Levels as a Primary Risk Factor for the Severity of COVID-19. medRxiv preprint doi: https://doi.org/10.1101/2021.04.29.21256294.
27. Lang LW, Zhu ZZ,, Xu Zand et al.(2022). The Association Between the Albumin and Viral Negative Conversion Rate in Patients Infected with Novel Coronavirus Disease 2019 (COVID-19). Infection and Drug Resistance: 15 1687–1694.
28. Polito C, Martin GS. (2013). Albumin: physiologic and clinical effects on lung function. Minerva Anestesiol; 79(10):1180–1186.
29. Huang W, Li C, Wang ZQ and et al. (2020). Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2623 hospitalized cases. Sci China Life Sci; 63(11):1678–1687.
30. Aldecoa C, Llau JV, Nuvials X and et al. (2020). Role of albumin in the preservation of endothelial glycocalyx integrity and the microcirculation: a review. Ann Intensive Care; 10(85):1-12.
- Article View: 27
- PDF Download: 20